# A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

> **NCT05536791** · — · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Dabigatran Etexilate (DE)

## Key facts

- **NCT ID:** NCT05536791
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-24
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were screened in the study.
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05536791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05536791, "A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05536791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*